What are CJC-1295 and tesamorelin?
Start with the part they share. Both are GHRH analogs. GHRH — growth-hormone-releasing hormone — is a small peptide your hypothalamus makes that travels a short distance to your pituitary gland and tells it to release growth hormone (GH). Growth hormone is the body's own signal involved in tissue repair, muscle and bone, and how the body handles fat. So a "GHRH analog" is a lab-made molecule that mimics that natural instruction: instead of injecting growth hormone directly, it nudges your own pituitary to release more of its own GH, in the natural pulsing pattern.
CJC-1295 is a synthetic long-acting version of the active fragment of GHRH (the first 29 amino acids). It was chemically modified to resist the enzymes that normally chew up natural GHRH within minutes — which is the whole point of it, because that modification lets a single dose keep stimulating GH for days rather than minutes. You will also see a closely related shorter-acting form sold as "Mod GRF 1-29" or "CJC-1295 without DAC."
Tesamorelin is also a stabilized GHRH analog, but it took a very different path: it became an actual approved medicine, sold under the brand name Egrifta. It was developed, tested in randomized trials, and reviewed by the FDA for a specific medical problem. That difference in path — research chemical versus reviewed medicine — is the entire story of this comparison, so it is worth pulling out on its own.
The big difference: approved vs unapproved
Here is the single most important thing to understand before any talk of mechanisms or doses: these two peptides are not on equal footing in the eyes of regulators. Tesamorelin is an FDA-approved drug. CJC-1295 is not approved for anything, anywhere.
"FDA-approved" is not a vibe or a marketing badge — it means a manufacturer ran controlled human trials, submitted them, and a regulator reviewed the evidence and agreed the drug is safe and effective for a defined use at a defined dose, with a defined label. Tesamorelin cleared that bar. CJC-1295 never entered it: there is no completed New Drug Application, no approved label, and no agency-approved indication for CJC-1295. It is sold as a "research chemical," typically labeled "for research use only" or "not for human consumption" — a disclaimer that lets a vendor sell it outside the drug-regulation system, not a sign that anyone has confirmed it is safe or works.
That asymmetry colors everything else on this page. When you read that tesamorelin reduced fat in a trial, that figure comes from a regulated, peer-reviewed study in the population it was approved for. When you read what CJC-1295 "does," you are almost always reading about early pharmacology — what it does to a hormone level in the blood — not proof that it produces a health benefit anyone tested and confirmed. Keep that distinction in mind for the rest of this comparison.
What is tesamorelin actually approved for?
Tesamorelin has exactly one FDA-approved indication, and it is narrower than most people assume: the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. That is the whole scope of the approval — not general weight loss, not body recomposition, not anti-aging, and not "GH optimization" in otherwise healthy people.
HIV-associated lipodystrophy is a recognized condition in which some people living with HIV, often in connection with certain older antiretroviral therapies, accumulate excess visceral fat — the deep fat packed around the abdominal organs — frequently alongside metabolic changes. Tesamorelin was developed, trialed, and approved specifically to address that fat in that population. In the pivotal 2007 trial published in the New England Journal of Medicine, visceral adipose tissue fell about 15.2% over 26 weeks on tesamorelin while rising about 5.0% on placebo, and the drug raised IGF-1 (the downstream messenger of growth hormone) by roughly 81%, confirming it was engaging the GHRH-to-GH axis as intended.
Two things on the approved label matter for honesty here. First, tesamorelin is explicitly NOT indicated for weight-loss management — the label describes a weight-neutral effect, meaning it shifts where fat sits rather than lowering the number on the scale. Second, the label states that long-term cardiovascular benefit and safety have not been established. So even the approved use comes with stated limits, and the approved 2 mg-per-day dose belongs to that one disease, supervised by a clinician who monitors blood sugar and IGF-1 — it is not a generic "tesamorelin dose" for everyone, and it is not evidence that off-label anti-aging use is safe or effective.
What's the evidence for CJC-1295?
This is where being honest matters most, because the gap between how CJC-1295 is marketed and what has actually been tested in people is wide. The short, accurate answer: there is essentially no rigorous human efficacy evidence for CJC-1295. No published randomized controlled trial shows that it produces a confirmed health, body-composition, or anti-aging benefit in people. The popular claims attached to it are extrapolations from its hormonal effects, not from outcome studies.
What does exist is early pharmacology. The most-cited human work is a 2006 study in the Journal of Clinical Endocrinology & Metabolism — two small, randomized, placebo-controlled ascending-dose trials in healthy adults. It showed that a single subcutaneous dose raised average growth hormone levels roughly 2- to 10-fold for six days or more, and raised IGF-1 about 1.5- to 3-fold for nine to eleven days, with an effective half-life of roughly 5.8 to 8.1 days. That is a genuine, verified finding — but read what it is and is not. It demonstrates that CJC-1295 does what a long-acting GHRH analog is designed to do at the hormone level. It does not demonstrate that raising GH and IGF-1 this way makes anyone healthier, leaner, stronger, or younger, and it was never designed to.
There is also no approved or validated dose for CJC-1295. The microgram-per-kilogram amounts used in that study were dose-finding research quantities, not a therapy anyone established. Any specific dosing schedule you see quoted online is unvalidated — it is not drawn from an approved label or from a completed efficacy trial, because neither exists. In plain terms: CJC-1295 moves a hormone in early studies, and that is about as far as the verified human evidence goes.
How do their mechanisms compare?
On paper, the two are mechanistic cousins. Both are GHRH analogs, so both work the same upstream way: rather than supplying growth hormone directly, they stimulate the pituitary to release the body's own GH in pulses, which then signals the liver to make IGF-1, the messenger behind many of GH's tissue-level effects. This is generally considered more physiological than injecting GH itself, because it preserves the body's natural feedback loop that reins in GH excess.
The practical differences are about engineering and proof, not the core pathway. CJC-1295 was specifically built for an unusually long duration of action — its modifications let one dose keep stimulating GH for days, which is why early studies measured IGF-1 staying elevated for over a week. Tesamorelin's stabilization is more modest, and it was studied and approved as a once-daily injection. But the deeper difference is not chemical: tesamorelin's mechanism was carried all the way through to a measured clinical outcome (less visceral fat) in the approved population, whereas CJC-1295's mechanism has only been measured at the hormone level. A shared mechanism does not mean shared evidence.
Risks, and the research-grade-purity unknown
Honest risk reporting means separating two different things: what the molecule may do, and what the product itself introduces. On the molecule side, both peptides act through the GH pathway, so they share the side-effect themes seen with GH stimulation. In tesamorelin's approved trials, the tracked effects included joint pain (arthralgia), fluid retention and swelling (peripheral edema), injection-site reactions, and the potential for glucose intolerance — which is why the approved protocol builds in glucose and IGF-1 monitoring, and why the label carries contraindications including active malignancy and pregnancy. Raising IGF-1 is also the theoretical basis for the most-discussed long-term concern with any GH-axis agent: whether sustained stimulation could promote abnormal tissue growth. That question is monitored, not fully resolved, even for the approved drug.
For CJC-1295, the picture is murkier precisely because it was never carried through the same testing. The FDA, in reviewing it as a compounding substance, flagged cardiovascular concerns — an increased heart rate and a systemic vasodilatory reaction (flushing, warmth, transient drops in blood pressure) — among the reasons for caution. There is no long-term human safety database for it, because the studies that would build one were never done.
Then there is the risk that has nothing to do with pharmacology: the product itself. Because CJC-1295 is sold research-use-only and labeled "not for human consumption," the material that reaches a buyer is not manufactured, tested, or released as a medicine. There is no approved source, so what is actually in a given vial — its true identity, peptide purity, dose accuracy, endotoxin level, and sterility for injection — is not guaranteed. For an injectable used outside any regulated supply chain, contamination and mislabeling are real, documented categories of risk that exist independently of whatever the peptide may or may not do. Tesamorelin, when dispensed as the approved medicine through a licensed pharmacy, does not carry that particular unknown — though off-label or gray-market sourcing of any peptide reintroduces it.
Are they banned in sport?
Yes — and this is a place where the approved-versus-unapproved divide does not protect you. The World Anti-Doping Agency prohibits growth-hormone-releasing factors, and its Prohibited List explicitly covers GHRH and its analogues under section S2.2.4, banned at all times, in and out of competition. Both CJC-1295 and tesamorelin fall in that category.
So the fact that tesamorelin is an FDA-approved medicine does not make it permissible for a tested athlete — the approval line and the anti-doping line are simply different lines. For anyone subject to drug testing, both peptides are an anti-doping rule violation waiting to happen, and modern testing can detect them for days after a dose. This is one of the clearer practical takeaways of the whole comparison: regulatory approval and competitive legality are not the same thing.
Who should you ask?
The honest bottom line is that "CJC-1295 vs tesamorelin" is not a question you can settle from a webpage, and it is definitely not a dosing decision to make on your own. Whether either peptide has any place for you — and if so, which, at what dose, for what reason, and with what monitoring — is a clinical judgment that belongs to a licensed clinician who can evaluate your full medical history.
A clinician weighs things an article cannot: your glucose tolerance and diabetes risk, joint and cardiovascular status, any history of cancer or pituitary issues (contraindications on the tesamorelin label), what you are actually trying to achieve, and crucially whether your intended use is an approved indication or an off-label, unvalidated one. For tesamorelin, off-label use outside HIV-associated lipodystrophy means leaving the evidence base behind. For CJC-1295, there is no approved use to leave — it is investigational by definition.
PeptidePanel does not sell, source, supply, prescribe, or endorse any compound, and nothing here is medical advice. CJC-1295 is unapproved and of unproven safety and efficacy in humans; tesamorelin is approved only for one narrow condition. Either decision belongs with a qualified physician.
Tracking either protocol on PeptidePanel
If a clinician has put you on a GHRH-analog protocol, the day-to-day record is where it succeeds or quietly drifts — and that record is easy to lose track of in your head. PeptidePanel is the neutral monitoring layer for exactly that work: logging each injection, charting the trends that matter, and tracking the labs a clinician watches on this kind of protocol — IGF-1 against age-matched reference ranges, and fasting glucose and HbA1c to catch glucose dysregulation early — so both you and your clinician have a clear, quantitative picture of how things are going.
PeptidePanel does not supply, recommend, or prescribe anything. It is simply the organized notebook for the plan a qualified prescriber has set — and the safest way to use any GH-axis compound is under that kind of monitoring, not a dosing chart found online.